Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011489 | 1.00 | ADORA2B (0.48) | ADORA2BADORA3CYP1A2TLR7GRIN1 | |
| SCHEMBL30012916 | 0.79 | ADORA3 (0.50) | ADORA2BADORA3GRIN1GRIN2B | |
| SCHEMBL30012911 | 0.79 | ADORA3 (0.50) | ADORA2BADORA3GRIN1GRIN2B | |
| SCHEMBL30110524 | 0.79 | ADORA3 (0.42) | ADORA2BADORA3CYP1A2GRIN1GRIN2B | |
| SCHEMBL23202127 | 0.79 | ADORA3 (0.42) | ADORA2BADORA3CYP1A2GRIN1GRIN2B | |
| SCHEMBL31392649 | 0.79 | ADORA3 (0.42) | ADORA2BADORA3GRIN1GRIN2B | |
| SCHEMBL23202362 | 0.76 | GRIN1 (0.51) | GRIN1GRIN2BPDE4APDE4BPDE4C | |
| SCHEMBL30011997 | 0.76 | GRIN1 (0.51) | GRIN1GRIN2BPDE4APDE4BPDE4C | |
| SCHEMBL23202181 | 0.68 | ADORA3 (0.43) | ADORA2BADORA3GLA | |
| SCHEMBL31392722 | 0.66 | ADORA2B (0.51) | ADORA2BADORA3GLABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055132-A1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187759-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240116974-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021108649-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108649-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
| EP-3801538-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155652-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885CYP1A2 1067/4885 |
| US-11059824-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | ADORA2B 63/4885ADORA3 42/4885CYP1A2 1450/4885 |
| US-20260055132-A1 | TLR7 AGONISTS | TLR7, TLR8, TLR1 | ADORA2B 612/4885ADORA3 273/4885CYP1A2 964/4885 |
| US-20240116974-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885CYP1A2 1067/4885 |
| US-12187759-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885CYP1A2 1067/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | ADORA2B 63/4885ADORA3 42/4885CYP1A2 1450/4885 |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | ADORA2B 63/4885ADORA3 42/4885CYP1A2 1450/4885 |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | ADORA2B 63/4885ADORA3 42/4885CYP1A2 1450/4885 |
| US-11692005-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | ADORA2B 390/4885ADORA3 354/4885CYP1A2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.